{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-029057","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.149887+00:00","generated_at":"2026-06-05T06:29:52.841138+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Iovance reports $485M cash, AMTAGVI launch ongoing; partial clinical hold on lung TIL trial","bullets":["Cash position ~$485M as of 2/22/24, including $197.1M from Feb 2024 equity offering.","AMTAGVI (lifileucel) approved for advanced melanoma; 30 active ATCs at launch, targeting ~50 within 90 days.","FDA placed partial clinical hold on IOV-LUN-202 NSCLC trial on Dec 22, 2023; enrollment paused.","Phase 3 TILVANCE-301 frontline melanoma trial randomized first patient in 2Q23.","Proleukin acquired for £167.7M upfront; global rights secured for IL-2 supply in AMTAGVI regimen."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-029057","json":"https://secwatch.observer/filing/0001104659-24-029057.json","markdown":"https://secwatch.observer/filing/0001104659-24-029057.md","text":"https://secwatch.observer/filing/0001104659-24-029057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924029057/0001104659-24-029057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924029057/tm247560d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T06:29:52.841138+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}